Long-Term Clopidogrel Monotherapy After Percutaneous Coronary Intervention: Will the Pupil Surpass the Master?
- PMID: 37821167
- DOI: 10.1016/j.jacc.2023.08.035
Long-Term Clopidogrel Monotherapy After Percutaneous Coronary Intervention: Will the Pupil Surpass the Master?
Keywords: aspirin; bleeding; clopidogrel; ischemic events; percutaneous coronary intervention.
Conflict of interest statement
Funding Support and Author Disclosures Dr Sabaté has received consultant fees from Abbott Vascular and iVascular outside of the submitted work. Dr Angiolillo has received consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, CSL Behring, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, Novartis, PhaseBio, PLx Pharma, Pfizer, Sanofi, and Vectura; and his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, Celo-Nova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co, Merck, Novartis, and the Scott R. MacKenzie Foundation. Dr Ortega-Paz has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.J Am Coll Cardiol. 2023 Oct 17;82(16):1565-1578. doi: 10.1016/j.jacc.2023.07.031. J Am Coll Cardiol. 2023. PMID: 37821166 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
